Hansoh Pharma’s BLA for B7-H3 ADC HS-20093 Accepted by China’s NMPA
Bulletin Express
Sep 24
Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) accepted the biologics license application (BLA) for its proprietary antibody-drug conjugate (ADC) risvutatug rezetecan (HS-20093) on 24 September 2026. The application seeks approval to treat osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy. HS-20093 targets the B7-H3 antigen and represents an innovative addition to the Group’s oncology pipeline. Chairlady Zhong Huijuan signed the voluntary disclosure on behalf of the board.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.